216 related articles for article (PubMed ID: 31095714)
1. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
Miccio J; Johung K
Oncology (Williston Park); 2019 May; 33(5):167-73, 177. PubMed ID: 31095714
[TBL] [Abstract][Full Text] [Related]
2. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.
Miccio JA; Oladeru OT; Jun Ma S; Johung KL
Urol Clin North Am; 2020 Aug; 47(3):399-411. PubMed ID: 32600541
[TBL] [Abstract][Full Text] [Related]
3. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
[TBL] [Abstract][Full Text] [Related]
5. [German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist].
Müller AC; van Oorschot B; Micke O; Guckenberger M
Strahlenther Onkol; 2018 Jan; 194(1):1-8. PubMed ID: 28819766
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?
Carrasco-Esteban E; Barrionuevo-Castillo P; Domínguez-Rullán J; Gómez-Aparicio MA; Ferri-Molina M; Sáez-Bueno P; Zalabarría-Zarrabeitia Z; Scorsetti M; Arcangeli S; López-Campos F; Couñago F
Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):163-176. PubMed ID: 36443137
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature.
Francolini G; Detti B; Ingrosso G; Desideri I; Becherini C; Carta G; Pezzulla D; Caramia G; Dominici L; Maragna V; Teriaca MA; Bottero M; Livi L
Crit Rev Oncol Hematol; 2018 Nov; 131():24-29. PubMed ID: 30293702
[TBL] [Abstract][Full Text] [Related]
10. Role of Radiation in Treatment of Renal Cell Carcinoma.
Leeman JE
Hematol Oncol Clin North Am; 2023 Oct; 37(5):921-924. PubMed ID: 37246085
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
[TBL] [Abstract][Full Text] [Related]
12. Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma.
Reddy AV; Mills MN; Liauw SL; Baliga S; Kersh CR
Can J Urol; 2019 Apr; 26(2):9743-9745. PubMed ID: 31012841
[TBL] [Abstract][Full Text] [Related]
13. [The therapeutic potential of ablative radiotherapy for metastatic renal cell cancer: a tumour deemed radiation resistant].
Coucke P; Jánváry Z; Jansen N
Rev Med Liege; 2014; 69 Suppl 1():94-100. PubMed ID: 24822313
[TBL] [Abstract][Full Text] [Related]
14. [A systematic review of radiotherapy for primary renal cell carcinoma].
Gladilina IA; Shabanov MA; Kushlinskii NE; Bliganov PI; Sergeev AN
Urologiia; 2022 Mar; (1):96-101. PubMed ID: 35274868
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy for renal-cell carcinoma.
De Meerleer G; Khoo V; Escudier B; Joniau S; Bossi A; Ost P; Briganti A; Fonteyne V; Van Vulpen M; Lumen N; Spahn M; Mareel M
Lancet Oncol; 2014 Apr; 15(4):e170-7. PubMed ID: 24694640
[TBL] [Abstract][Full Text] [Related]
16. SBRT in Localized Renal Carcinoma: A Review of the Literature.
DE LA Pinta C; Latorre RG; Fuentes R
Anticancer Res; 2022 Feb; 42(2):667-674. PubMed ID: 35093865
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M
Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
[TBL] [Abstract][Full Text] [Related]
20. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
